Discover
Breaking Innovation Paralysis
Breaking Innovation Paralysis
Author: Natalie Yeadon, Founder and CEO, Augmentios
Subscribed: 0Played: 0Subscribe
Share
© Natalie Yeadon, Founder and CEO, Augmentios
Description
Canada builds world-class cures and companies, then consistently loses them. Breaking Innovation Paralysis investigates why, through candid conversations with the founders, scientists, and policymakers living this reality every day. Host Natalie Yeadon, a former clinician, pharmaceutical executive, and tech entrepreneur who built and exited a global Canadian company, traces the problem to three forces: inertia, risk aversion, and diffusion of responsibility. Each episode goes inside a different layer of the system, from university labs to government policy, to find out how to fix.
19 Episodes
Reverse
Dr. J. Ari Pandes is Associate Dean, Professional Graduate Programs, and Associate Professor of Finance at the University of Calgary's Haskayne School of Business, where he has taught and researched for 17 years and also serves as Finance Area Chair and Director of the MBA and Executive MBA programs. His research covers investment banking, securities issuance, IPOs, private equity and venture capital, and the decision to go public. With Dr. L. Daniel Wilson of the University of Calgary's Faculty of Law, he leads the Canadian Public Company Study, a national survey of executives and capital markets professionals on why public listings are falling and what would make listing attractive again. He writes regularly for The Globe and Mail, the Financial Post and the Calgary Herald, most recently with Jay Ritter, known as "Mr. IPO." He holds a PhD in finance and economics from York University's Schulich School of Business.Ari's interest in IPOs began as a PhD student researching the bought deal, the underwriting arrangement Gordon Capital used to shake up Bay Street. He explains why intermediaries matter so much: they connect companies that need capital with the people who provide it. After the 1987 changes to the Bank Act, Canada's big banks moved into underwriting and now handle 60 to 80 percent of equity deals in some years, while the specialized independent dealers that once championed small companies were squeezed out. Intermediaries, he says, are "the oil and the grease that allow the economy and capital raising to function."The number of senior operating companies listed in Canada has fallen by nearly half since 2008. IPOs dropped from about 35 a year between 1986 and 2000 to about 12, and only three or four in some recent years. Executives surveyed in his national study point first to the cumulative weight of regulation and disclosure. At the same time, private capital has grown so large that companies can stay private for longer. That works for American companies, but Canada lacks the same deep private pools, so its best high-growth companies get "picked off too early," usually by U.S. buyers, and Canada ends up with few anchor companies left to buy and build the next generation.Ari then tells the origin story of the Capital Pool Company program. After oil prices collapsed in the 1980s, Alberta regulators turned the blind pools that U.S. promoters had abused into a regulated way for small companies to go public. The program now lives on the TSX Venture Exchange and was the forerunner of the American SPAC, which he calls "CPCs on steroids." His research shows that companies that start on the TSX Venture Exchange and graduate to the senior market outperform those that go straight to the TSX. He also discusses Ontario's decision to join the securities passport system, proportionate regulation for smaller companies, and why public markets let founders keep control of their business while giving everyday savers access to growth that would otherwise stay in private hands.Looking at Budget 2026, Ari wanted more incentives to go public and a level playing field based on a company's size rather than its listing status. He calls for a national task force on Canada's capital markets and, as the Senate banking committee recommended, a minister for small and medium-sized enterprises.Ari's message: make Canada's public markets worth using again, so companies can build, list and scale here.🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.📈 Breaking Innovation Paralysis is a top-50 Life Sciences podcast on Apple Podcasts in Canada. Following the show on Apple Podcasts helps more people find these conversations.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter
Dr. Kyle Briggs is a physicist, entrepreneur and one of Canada’s clearest voices on how research becomes economic impact. During his PhD at the University of Ottawa, in Professor Vincent Tabard-Cossa’s lab, he helped develop a simple, low-cost way to make solid-state nanopores, tiny holes that read molecules through electrical signals. He co-founded Northern Nanopore Instruments to bring that work to market and led it as CEO until its acquisition by Oxford Nanopore Technologies in 2023. Today he is Entrepreneur in Residence for uOttawa’s Faculty of Science. He co-authored the Simple Agreement for Innovation Licensing (SAIL) with David Durand and TJ Misra, and co-founded the SAIL Fund, a venture philanthropy fund for companies built on publicly funded research. He writes the CanInnovate newsletter, testified before the House of Commons Standing Committee on Science and Research in 2025, and was named one of Ottawa’s Forty Under 40 in 2026.Kyle starts with the moment his lab replaced a million-dollar electron microscope with a nine-volt battery, and how Northern Nanopore sold its first instruments to nanopore labs around the world from day one. Revenue let the company grow without dilutive funding, but not by choice. He describes a catch-22 common to Canadian deep tech founders: funders want technical milestones before they invest, and founders need funding to reach those milestones. When the acquisition offer came, the team made one last attempt to raise in Canada. “Selling was the right decision at the time because it was the only decision at the time.”He explains why the U.S. Bayh-Dole Act and the SBIR program work in an ecosystem with deep early-stage capital and huge public demand for innovation, and why other countries that copied them got weaker results. In Canada, every university has its own IP policy and almost every licence is negotiated from scratch, with no national data on what happens next. SAIL offers one standard licence that works under any Canadian institution’s IP policy for most spinouts. Kyle also looks at incentives inside universities, from tenure reviews that count only publications to technology transfer offices funded on licensing revenue that, in Canada, adds up to less than 2% of research spending.Kyle then makes the case for venture philanthropy. Because value from academic IP follows a power law, a few successes pay for many failures, and risk has to be managed across a portfolio, not project by project. Public programs that require matching funds or pay out only after the work is done are out of reach for pre-revenue startups. His simulations show that private investors would need to wait decades for confident returns. Blended funds such as the UK’s UKI2S fill that gap. Almost 80% of the companies it backed say they owe their existence to that first cheque.Kyle’s message: Canada already has the research, and making use of it is now a matter of economic security.This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.If this shifted how you think about Canada’s innovation gap, share it with someone who needs to hear it.🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada’s innovation journey.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter#BreakingInnovationParalysis #CanadianInnovation #TechTransfer #UniversitySpinouts #IntellectualProperty #VenturePhilanthropy #DeepTech
Dan Wasserman is the founder and CEO of Mammoth Health Innovation and the creator of CHIEFS (Customers, Health Economics, Impact, Execution, Financials and Scalability), a tool that benchmarks a Canadian health innovation against an American one at the same stage of development, then lays out the actions needed to level the playing field. Over a 40-year career, with the past 28 years split between Canada and the United States, Dan has worked in competitive intelligence, IP insights and business development for IBM, AT&T, Hollywood studios, airlines and banks. He also spent a decade in Washington, DC, including lobbying on Capitol Hill. He mentored early-stage companies at ventureLAB, where he created the Health Ecosphere program before spinning out Mammoth, and he is an adjunct professor in the innovation stream at the Icahn School of Medicine at Mount Sinai. Dan holds a biology degree from the University of Toronto and an MBA from the Schulich School of Business, and he is a published novelist.Dan opens with a story about commercial creativity. In the mid-1990s, Sympatico, the phone companies’ new internet service, was falling far short of its sign-up target. Dan struck a deal with Christie to put instant-win Sympatico offers inside Oreo packages across the country. The launch finished the year with 140,000 sign-ups against a goal of 100,000, and “the only thing Christie insisted we pay for was the $300 in colour separations.”From there, he compares how the two countries think about commercialization. In the US, SBIR and STTR funding expects a commercialization plan, and investors ask founders how they deployed that money and whether they have pre-sales. In Canada, he sees strong support for research and far less for getting products to market. He describes the Health Ecosphere he built at ventureLAB, which brought together finance, legal, IP, government and hospital partners after health system leaders said they welcomed innovation and the companies in the room said they couldn’t get through the door. The work later received FedDev funding, and Dan sees its legacy in CAN Health Network and OBIO’s Early Adopter Health Network.Dan then walks through how CHIEFS came to be. He started from 50 criteria that separate American successes from Canadian ones, distilled them into 10 factors, and organized them into six pillars. A factors report shows innovators where they need to pull their socks up, and a pillars profile tells investors whether a company is worth considering. Execution is where companies fall down most often, he says, and the smartest scientific founders bring in business people early, because “100% of zero is still zero.”The conversation closes on what it takes to keep companies in Canada. Dan makes the case for exits to Canadian buyers backed by Canadian pension capital, and traces part of the problem to the 1990s Bank Act changes. He explains what Canada should copy from the holding-period rules in the US QSBS program, and why US funders back several competitors at once so that failure isn’t a penalty. He also talks about Canada’s shortage of commercialization talent, what Estonia’s integrated digital systems show is possible, and why drugs designed by AI still have to prove themselves in human trials.Dan’s message is that Canada already pays for the science, and the next step is building commercialization into how we fund, buy and keep our innovations.If this shifted how you think about Canada’s innovation gap, share it with someone who needs to hear it.🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada’s innovation journey.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter#BreakingInnovationParalysis #CanadianInnovation #Commercialization #HealthInnovation #Procurement #VentureCapital #HealthPolicy
Ayotola Ogunsipe is a pharmacist turned market access leader who sits at the intersection of private payers and the pharmaceutical industry. As Senior Advisor, Business Development at Express Scripts Canada, he represents insurers such as Manulife and Desjardins when manufacturers’ market access teams bring new therapies to Canada. He began his career as a pharmacist in Nigeria, earned a Master of Science in Pharmacology from the University of Lagos, led medical services for a major Lagos electricity utility, and co-founded a last-mile delivery company that brought prescription medications from retail pharmacies to patients. He came to Canada for his MBA at the Ivey Business School at Western University, where he was co-president of the Health Sector Club. He then worked as a RISE Fellow at Marsh McLennan and as a business consultant in Payer Solutions at TELUS Health. He is a certified Project Management Professional and Financial Modeling and Valuation Analyst, and writes regularly about market access, drug pricing and Canada’s life sciences ecosystem.Ayotola starts behind the pharmacy counter, where patients kept leaving without their medication because of back orders. That experience still shapes how he negotiates today: “it’s one thing to get a product listed on a formulary,” he says, but patients also need to get it at the right time. He then looks at insulin and GLP-1s, two classes of medicine that grew out of Canadian science and that Canada now negotiates to buy back, and asks how the country could keep licensing, ownership and value at home.He explains why clinical trials run in Canada matter long after the trial ends. When Canadian physicians and Canadian patients generate the data, reviewers have more confidence in it, and coverage decisions can move faster. He walks through the long road from Health Canada approval to coverage: health technology assessment by CDA or INESSS, negotiation with the pan-Canadian Pharmaceutical Alliance, and provincial listing. Together, these steps can mean a drug approved in 2026 isn’t covered until 2028.The conversation turns to most favoured nation pricing in the US, and why some manufacturers are now launching to private plans first and delaying public negotiations. Ayotola explains how that moves risk onto private payers and employers, why he expects premiums to rise, and why he thinks drugs discovered with AI may raise costs before they lower them.His message is that approval and access are two very different things, and Canada has to manage both.This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.If this shifted how you think about Canada’s innovation gap, share it with someone who needs to hear it.🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada’s innovation journey.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter#BreakingInnovationParalysis #CanadianInnovation #MarketAccess #DrugPricing #ClinicalTrials #PharmaPolicy #LifeSciences
Neelam Bance is a health care entrepreneur who spent most of her career in the pharmaceutical industry, in sales and marketing across diabetes, mental health, neurology and oncology at companies like Eli Lilly and Sunovion, before moving into health technology and precision medicine. She co-founded MedGeneius, a software platform that translates pharmacogenetic test results into guidance that helps clinicians choose the medications most likely to work for each patient. She is now co-founder and CEO of ODINsight Canada, which aims to securely connect Canada’s health data contributors and beneficiaries to fuel breakthroughs, accelerate innovation and drive economic growth. She is also Director of Business Development, Specialty Therapeutics, at Auxilium Health. Neelam founded the Asha Alliance, sits on the board of Yellow Brick House, and holds an MBA from the Schulich School of Business and a biology degree from the University of Toronto.Neelam starts with what pharma taught her, and why it began to feel like “rinse and repeat”: global teams set the strategy, and Canada localized it. A sudden personal upheaval made her fearless. She asked herself what the worst that could happen really was, and for the first time in her life she took a chance on herself.She then takes us inside pharmacogenomics, where she says 99% of people, including many physicians, don’t know what the test is. Pharma launches drugs with armies of reps and medical science liaisons. Pharmacogenomic companies have to raise awareness across every specialty with a fraction of those resources. She explains why payers look at the cost of a cheap antidepressant instead of the cost of a patient who never gets back to work, and how Ontario began funding DPYD testing only once the evidence of patients dying from a common chemotherapy drug became impossible to ignore.The conversation turns to building a company outside the university grant system. Neelam bootstrapped while juggling three jobs, and promoted the only product she had at first: herself. Her advice to academic founders is blunt: nothing sells itself. She explains how a chance conversation at a MaRS event with a Canadian who had advised the White House led to ODINsight Canada, a consortium designed to let private health data holders, from clinic medical records to insurers and start-ups, share what their data contains without handing it over. The aim is to make Canada a place where pharmaceutical companies want to run their trials.Her one lever for success is trust. Building it takes time, conversations and the right people in the room, which she calls “the Canadian way.”This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.If this shifted how you think about Canada’s innovation gap, share it with someone who needs to hear it. 🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada’s innovation journey.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact 📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter #BreakingInnovationParalysis #CanadianInnovation #HealthData #PrecisionMedicine #Pharmacogenomics #DigitalHealth #LifeSciences #ClinicalTrials




